Search results
Author(s):
Harriette Van Spall
,
Mikhail Kosiborod
Added:
1 year ago
AHA Conference 2024 — REALIZE-K: Impact of sodium zirconium cyclosilicate (SZC) on HFrEF patient's potassium levels whilst on spironolactone.Late-Breaker Host, Dr Harriette Van Spall (McMaster University, CA) is joined onsite by Dr Mikhail Kosiborod (Saint Luke's Mid America Heart Institute, US) to discuss the findings from the REALIZE-K Study (NCT04676646; AstraZeneca).REALIZE-K is a phase 4…
View more
Author(s):
Marianna Fontana
,
Added:
1 year ago
In this Meet the Experts session, from e-SPACE Heart Failure 2024, Prof Marianna Fontana and Prof Arnt Kristen explore the management of transthyretin amyloid cardiomyopathy (ATTRCM) and discuss strategies for optimising patient care pathways.
View more
Stephen J Greene
Research Area(s) / Expertise:
Author
Expertise
Heart FailureChronic Heart Failure ManagementHeart Failure Services, Prevention and Digital HealthGuidelines & StatementsMedication Optimisation and TitrationHeart Failure ComorbiditiesCardiovascular Kidney MetabolicCardiomyopathies and Cardiac AmyloidosisHeart Failure Diagnosis and ImagingCardiomyopathiesHeart Failure and Chronic Kidney DiseasePeripheral Artery Disease - GeneralPrevention & Chronic ConditionsVascular Disease and SurgeryHFpEF Pharmacological ManagementHFrEF Pharmacological ManagementChronic Kidney DiseaseAcute and Advanced Heart Failure
Wilfried Mullens
Research Area(s) / Expertise:
Job title: Heart Failure Clinician
Author
Robert Zukermann
Research Area(s) / Expertise:
Job title: Director of Intermediate Cardiac Care Unit
Author
Author(s):
Harriette Van Spall
,
Mikhail Kosiborod
Added:
2 years ago
HFA 2024 — Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) sat down with Dr Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, US) to discuss insights from the STEP-HFpEF programme.STEP HFpEF aimed to test the hypothesis that treatment with semaglutide can improve symptoms in patients with HFpEF and obesity. This discussion centers around the background of the…
View more
Riccardo M Inciardi
Research Area(s) / Expertise:
Job title: Medical Doctor, Cardiologist
Author
Author(s):
Added:
1 year ago
HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892).EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.Interview Questions:What is the…
View more
Veli-Pekka Harjola
Research Area(s) / Expertise:
Author
Expertise
Heart FailureChronic Heart Failure ManagementHeart Failure Services, Prevention and Digital HealthGuidelines & StatementsMedication Optimisation and TitrationHeart Failure ComorbiditiesCardiovascular Kidney MetabolicCardiomyopathies and Cardiac AmyloidosisHeart Failure Diagnosis and ImagingCardiomyopathiesHeart Failure and Chronic Kidney DiseasePeripheral Artery Disease - GeneralPrevention & Chronic ConditionsVascular Disease and SurgeryHFpEF Pharmacological ManagementHFrEF Pharmacological ManagementChronic Kidney DiseaseAcute and Advanced Heart Failure
John J Atherton
Research Area(s) / Expertise:
Author
Expertise
Heart FailureChronic Heart Failure ManagementHeart Failure Services, Prevention and Digital HealthGuidelines & StatementsMedication Optimisation and TitrationHeart Failure ComorbiditiesCardiovascular Kidney MetabolicCardiomyopathies and Cardiac AmyloidosisHeart Failure Diagnosis and ImagingCardiomyopathiesHeart Failure and Chronic Kidney DiseasePeripheral Artery Disease - GeneralPrevention & Chronic ConditionsVascular Disease and SurgeryHFpEF Pharmacological ManagementHFrEF Pharmacological ManagementChronic Kidney DiseaseAcute and Advanced Heart Failure